MeiraGTx (Nasdaq: MGTX) has announced that additional clinical data from the Phase 1/2 trial of botaretigene sparoparvovec for the treatment of X-linked Retinitis Pigmentosa (XLRP)… Read More »MeiraGTx (NASDAQ: MGTX), a UK gene therapy company, has announced preliminary efficacy data from a gene therapy for XLRP patients
A research team based at the National Eye Institute, National Institutes of Health, Bethesda, Maryland, has published long-term visual outcomes for patients participating with an… Read More »A real-world study on an AI-enabled tele-monitoring project shows significant impact on long-term outcomes.
Researches based in the Centre for Ophthalmology, Eberhard Karls University of Tübingen, Germany, has reported the natural course of disease progression, with respect to central… Read More »Genotype-Phenotype correlations in PDE6A associated with arRP shows the range of severity
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the May 10th, 2022 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »May 10th, 2022 “EURETINA-Brief”© Issue No. 254
Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced a strategic manufacturing services agreement with National Resilience, Inc.… Read More »Opus Genetics Inc., has announced a strategic manufacturing services agreement with National Resilience, Inc., for the development of LCA treatments
A research team based at the Rotterdam Eye Hospital, the University of Groningen and University Eye Clinic, Maastricht, has reported that idebenone (known as Raxone),… Read More »A national cohort study in the Netherlands have reported clinical outcomes of treatment with idebenone in Leber’s hereditary optic neuropathy (LHON)
Researches based in Canada, UK, Singapore and the USA has reported a comprehensive systematic review and meta analyses on the comparison of anti-VEGF regimens to… Read More »A systematic review and meta-analyses study has reported the efficacy, safety, and treatment burden of T&E, versus alternative anti-VEGF regimens for nAMD
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the April 20th, 2022 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »April 20th, 2022 “EURETINA-Brief”© Issue No. 253
Ocugen Inc., (NASDAQ:OCGN), an ophthalmic biopharmaceutical company based in Malvern, Pennsylvania, has announced that the first patient has been dosed in a Phase 1/2 clinical… Read More »Ocugen Inc., (NASDAQ: OCGN) has announced the launch of a Phase 1/2 study for a modifier gene therapy candidate treating retinitis pigmentosa (RP)
An Italian consortium of clinical researches from fourteen institutes has reported a longitudinal natural history of RPE65-assocaited retinopathies. The report, led Dr. Francesco Testa at… Read More »A longitudinal natural history of RPE65-associated retinopathies in Italy showed specific genotype-phenotype characteristics